Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Background Venous thromboembolism (VTE) is frequently observed in patients with
coronavirus disease 2019 (COVID‐19). However, reported VTE rates differ substantially …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Background Ambulatory patients receiving systemic cancer therapy are at varying risk for
venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is …

Background Patients with active cancer have an increased risk of venous thromboembolism,
which results in substantial morbidity, mortality, and health care expenditures. The Khorana …

D-dimer is a soluble fibrin degradation product that results from ordered breakdown of
thrombi by the fibrinolytic system. Numerous studies have shown that D-dimer serves as a …

The risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) associated
with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Pulmonary embolism is a common and potentially fatal cardiovascular disorder that must be
promptly diagnosed and treated. The diagnosis, risk assessment, and management of …